ArticleHaematologica2019

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Anton Hagenbeek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.